• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Favorito Tamara A

    3/1/24 8:53:09 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARTL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    FAVORITO TAMARA A

    (Last) (First) (Middle)
    505 LOMAS SANTA FE, SUITE 160

    (Street)
    SOLANA BEACH CA 92075

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ARTELO BIOSCIENCES, INC. [ ARTL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/28/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $22.8(1) 02/28/2024 D 2,000 (2) 03/05/2031 Common Stock 2,000(1) (3) 0 D
    Stock Option (right to buy) $15(4) 02/28/2024 D 667 06/23/2022 07/16/2031 Common Stock 667(4) (3) 0 D
    Stock Option (right to buy) $4.89(5) 02/28/2024 D 667 06/24/2023 06/24/2032 Common Stock 667(5) (3) 0 D
    Stock Option (right to buy) $1.99 02/28/2024 D 667 (6) 06/30/2033 Common Stock 667 (3) 0 D
    Stock Option (right to buy) $2.01 02/28/2024 D 1,083 (7) 08/04/2033 Common Stock 1,083 (3) 0 D
    Stock Option (right to buy) $1.55 02/28/2024 A 2,000 (8) 03/05/2031 Common Stock 2,000 (3) 2,000 D
    Stock Option (right to buy) $1.55 02/28/2024 A 667 (8) 07/16/2031 Common Stock 667 (3) 667 D
    Stock Option (right to buy) $1.55 02/28/2024 A 667 (8) 06/24/2032 Common Stock 667 (3) 667 D
    Stock Option (right to buy) $1.55 02/28/2024 A 667 (8) 06/30/2033 Common Stock 667 (3) 667 D
    Stock Option (right to buy) $1.55 02/28/2024 A 1,083 (8) 08/04/2033 Common Stock 1,083 (3) 1,083 D
    Explanation of Responses:
    1. This option was granted on March 5, 2021 and was previously reported as covering 30,000 shares at an exercise price of $1.52 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.
    2. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan (the "Plan")) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, one third (1/3rd) of the shares subject to the option shall vest on the two (2) year anniversary of the Vesting Commencement Date, one third (1/3rd) of the shares subject to the option shall vest on the three (3) year anniversary of the Vesting Commencement Date, such that the option shall be fully vested on the three (3) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 5, 2021.
    3. The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).
    4. This option was granted on July 16, 2021 and was previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.
    5. This option was granted on June 24, 2022 and was previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.
    6. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 30, 2023.
    7. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean August 4, 2023.
    8. Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024.
    /s/ Gregory D. Gorgas, as Attorney-in-Fact 03/01/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ARTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARTL

    DatePrice TargetRatingAnalyst
    11/1/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARTL
    SEC Filings

    See more
    • Artelo Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      6/13/25 5:10:52 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      5/23/25 4:30:39 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Artelo Biosciences Inc.

      10-Q - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

      5/13/25 8:22:40 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Favorito Tamara A

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:24:07 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Matsui Connie

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:21:52 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Pres, CEO, CFO, Treas & Secr Gorgas Gregory D.

      4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

      5/5/25 5:21:39 PM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artelo Biosciences Announces Reverse Stock Split

      SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that on May 20, 2025 Artelo's Board of Directors approved a 6-for-1 reverse stock split ("Reverse Split") of the Company's common stock ("Common Stock"). The Company's common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, June 13, 2025. The Board of Directors determined the 6-for-1 ratio to be appropriate in order to increase the

      6/11/25 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

      SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 (https://bpsasm.org/) that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain. Professor Saoirse O'Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study tit

      6/5/25 9:00:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

      SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today welcomed the publication of a comprehensive review in Neurobiology of Disease, titled "Fatty acid binding proteins and their involvement in anxiety and mood disorders," that underscores the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating mood and anxiety disorders. The peer-reviewed article was co-authored by Doctor Steven Laviolette, Professor in the Schulich School of

      6/2/25 9:00:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Artelo Biosciences with a new price target

      HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00

      11/1/21 6:29:39 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LADENBURG THALM/SH SH initiated coverage on Artelo Biosciences

      LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy

      2/12/21 7:33:23 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Artelo Biosciences with a new price target

      Ladenburg Thalmann initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $7.00

      2/12/21 7:14:55 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

      SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm

      5/4/21 8:00:00 AM ET
      $KTRA
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

      LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a

      3/9/21 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer

      LA JOLLA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as Senior Vice President and Chief Scientific Officer. Dr. Yates is an experienced senior pharmaceutical executive, having served most recently at AstraZeneca, in significant roles across a number of functional areas including development and commercial strategy, medical affairs, and business development. Notably, Dr. Yates has been extensively involved in the life-cycle managem

      2/16/21 8:30:00 AM ET
      $ARTL
      Biotechnology: Pharmaceutical Preparations
      Health Care